These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 30316903)

  • 1. Therapy-induced enrichment of cancer stem-like cells in solid human tumors: Where do we stand?
    Martins-Neves SR; Cleton-Jansen AM; Gomes CMF
    Pharmacol Res; 2018 Nov; 137():193-204. PubMed ID: 30316903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting ETS1 with RNAi-based supramolecular nanoassemblies for multidrug-resistant breast cancer therapy.
    Wu M; Liu X; Jin W; Li Y; Li Y; Hu Q; Chu PK; Tang G; Ping Y
    J Control Release; 2017 May; 253():110-121. PubMed ID: 28302581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin.
    Arabi L; Badiee A; Mosaffa F; Jaafari MR
    J Control Release; 2015 Dec; 220(Pt A):275-286. PubMed ID: 26518722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vatalanib sensitizes ABCB1 and ABCG2-overexpressing multidrug resistant colon cancer cells to chemotherapy under hypoxia.
    To KK; Poon DC; Wei Y; Wang F; Lin G; Fu LW
    Biochem Pharmacol; 2015 Sep; 97(1):27-37. PubMed ID: 26206183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The palladacycle, BTC2, exhibits anti-breast cancer and breast cancer stem cell activity.
    Kimani S; Chakraborty S; Irene I; de la Mare J; Edkins A; du Toit A; Loos B; Blanckenberg A; Van Niekerk A; Costa-Lotufo LV; ArulJothi KN; Mapolie S; Prince S
    Biochem Pharmacol; 2021 Aug; 190():114598. PubMed ID: 33979647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ErbB/HER family of protein-tyrosine kinases and cancer.
    Roskoski R
    Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chinese medicine Bu-Fei decoction attenuates epithelial-mesenchymal transition of non-small cell lung cancer via inhibition of transforming growth factor β1 signaling pathway in vitro and in vivo.
    He XR; Han SY; Li XH; Zheng WX; Pang LN; Jiang ST; Li PP
    J Ethnopharmacol; 2017 May; 204():45-57. PubMed ID: 28412214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tamoxifen enhances erlotinib-induced cytotoxicity through down-regulating AKT-mediated thymidine phosphorylase expression in human non-small-cell lung cancer cells.
    Ko JC; Chiu HC; Syu JJ; Jian YJ; Chen CY; Jian YT; Huang YJ; Wo TY; Lin YW
    Biochem Pharmacol; 2014 Mar; 88(1):119-27. PubMed ID: 24447935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperbranched-hyperbranched polymeric nanoassembly to mediate controllable co-delivery of siRNA and drug for synergistic tumor therapy.
    Jia HZ; Zhang W; Zhu JY; Yang B; Chen S; Chen G; Zhao YF; Feng J; Zhang XZ
    J Control Release; 2015 Oct; 216():9-17. PubMed ID: 26272764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Irinotecan: 25 years of cancer treatment.
    Bailly C
    Pharmacol Res; 2019 Oct; 148():104398. PubMed ID: 31415916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting cancer epigenetic pathways with small-molecule compounds: Therapeutic efficacy and combination therapies.
    Wang Y; Xie Q; Tan H; Liao M; Zhu S; Zheng LL; Huang H; Liu B
    Pharmacol Res; 2021 Nov; 173():105702. PubMed ID: 34102228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer.
    Zalba S; Contreras AM; Haeri A; Ten Hagen TL; Navarro I; Koning G; Garrido MJ
    J Control Release; 2015 Jul; 210():26-38. PubMed ID: 25998052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting LRP6: A new strategy for cancer therapy.
    Xue W; Zhu B; Zhao K; Huang Q; Luo H; Shou Y; Huang Z; Guo H
    Pharmacol Res; 2024 Jun; 204():107200. PubMed ID: 38710241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer stem cells: how can we target them?
    Ischenko I; Seeliger H; Schaffer M; Jauch KW; Bruns CJ
    Curr Med Chem; 2008; 15(30):3171-84. PubMed ID: 19075661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3D cell culture systems modeling tumor growth determinants in cancer target discovery.
    Thoma CR; Zimmermann M; Agarkova I; Kelm JM; Krek W
    Adv Drug Deliv Rev; 2014 Apr; 69-70():29-41. PubMed ID: 24636868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of estrogen on targeted cancer therapy drugs.
    Zhao Y; Wang X; Liu Y; Wang HY; Xiang J
    Pharmacol Res; 2022 Mar; 177():106131. PubMed ID: 35167895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective targeting of cancer stem cells: a new concept in cancer therapeutics.
    Korkaya H; Wicha MS
    BioDrugs; 2007; 21(5):299-310. PubMed ID: 17896836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-cancer effects of naturally derived compounds targeting histone deacetylase 6-related pathways.
    Lernoux M; Schnekenburger M; Dicato M; Diederich M
    Pharmacol Res; 2018 Mar; 129():337-356. PubMed ID: 29133216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Cancer Stem Cells in Recurrent and Drug-Resistant Lung Cancer.
    Suresh R; Ali S; Ahmad A; Philip PA; Sarkar FH
    Adv Exp Med Biol; 2016; 890():57-74. PubMed ID: 26703799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Should we keep rocking? Portraits from targeting Rho kinases in cancer.
    de Sousa GR; Vieira GM; das Chagas PF; Pezuk JA; Brassesco MS
    Pharmacol Res; 2020 Oct; 160():105093. PubMed ID: 32726671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.